Advera Health Analytics, Inc. Receives Innovative Technology Designation from Vizient, Inc. for Evidex® Drug Safety Data Platform

Share Article

Designation recognizes products that bring improvements to the health care industry

Advera Health Analytics, Inc. announced its Evidex® drug safety data platform has received an Innovative Technology designation from Vizient, Inc. the largest member-driven health care performance improvement company in the country. The designation was based on reviews of Evidex by hospital experts who attended Vizient’s Innovative Technology Exchange in September 2016. The event provided medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from 1300 onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to an organization’s care and business model.

Evidex is a web-based platform that provides powerful drug safety insights using annotated data from curated clinical trials results and structured real world evidence. Powered by the proprietary RxFilter® data optimization technology, Evidex features on-demand pooled analyses, predictive identification of serious unknown drug safety risks, direct downstream medical cost calculations, and indication-wide drug safety scorecards.

Brian M. Overstreet, president of Advera Health Analytics said, “We’re excited and honored to receive the Innovative Technology designation from Vizient, Inc. for our Evidex drug safety data platform. This designation is especially rewarding because it is based on the reviews and feedback by hospital experts who assessed the impact our platform will have on improving clinical care and patient safety at Vizient member organizations. As a company with a mission to mitigate risk in the healthcare system by improving the transparency and actionability of drug safety data, we greatly appreciate being recognized as Innovative Technology for this important market.

“Due to the number of products and services being released and marketed as ‘innovative’, member hospitals truly value the peer-review system in place at Vizient to help them identify products worth further evaluation at their own facilities,” said Debbie Archer, director of procurement and leader of Vizient’s Innovative Technology program for suppliers. “After a review of the Evidex® drug safety data platform, Vizient’s member council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology designation.”

Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets’ Spend and Clinical Resource Management. Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient’s competitive bid cycle.

About Advera Health Analytics, Inc.
Advera Health Analytics was founded in 2010 by a group of passionate healthcare data entrepreneurs. Our mission is to mitigate risk in the healthcare system by improving the transparency and actionability of drug safety data. We do this by aggregating and curating large disparate datasets and deploying proprietary analytics to provide insight on the safety of marketed and pipeline drugs. Our goal is to become the gold standard resource for drug safety knowledge and insight across clinical trials, spontaneous reporting, and other real world evidence.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Overstreet
@AdveraHealth
Follow >
Visit website